Iodine 131 treatment for differentiated thyroid carcinoma in patients with end stage renal failure: dosimetric, radiation safety, and practical considerations. Hormones (Athens

I retention measurements performed post dialysis; in two of them some additional measurements such as iodine clearances were also performed. rEsULts: None of the patients experienced any short-term side effects, while they all had undetectable thyroglobulin levels on the first post therapy evaluation off thyroxine. 131 I elimination in the first haemodialysis was about 60%. staff incidental exposure and 131 I contamination were insignificant. cONcLUsIONs: On the basis of our experience, an empiric activity of 40-50% of that used for normal individuals appears to be effective as well as safe. these encouraging findings are discussed in relation with other reports in the literature